EuroBiotech Report—Lilly-CureVac, AstraZeneca-Brexit and more by Nick Paul Taylor Thursday, October 19, 2017 In this week's EuroBiotech Report, Lilly and CureVac pen $1.8 billion mRNA pact, AstraZeneca reveals Brexit pain, uniQure switches drugs and more.
InflaRx snags $55M for inflammatory, autoimmune trials by Nick Paul Taylor Friday, October 13, 2017 The series D follows fast after InflaRx established the potential of its anti-human complement factor C5a monoclonal antibody IFX-1 with phase 2 data.
German startup raises $34M for first-in-class complement inhibitor by Stacy Lawrence Thursday, July 21, 2016 InflaRx has raised $34 million in a Series C to at least get it through Phase II testing for its lead candidate, as well as to expand its preclinical pipeline.
